From the Research
C15, also known as compound 15, has shown potential therapeutic benefits, particularly in protecting cardiometabolic, immune, and liver health, as demonstrated in a recent study published in 2023 1. The study found that C15:0, an essential odd-chain saturated fatty acid, activates AMPK and inhibits mTOR, both of which are core components of the human longevity pathway.
- The study compared C15:0 with three longevity-enhancing candidates: acarbose, metformin, and rapamycin, and found that C15:0 had the most clinically relevant, dose-dependent activities.
- At their optimal doses, C15:0 (17 µM) and rapamycin (9 µM) shared 24 activities across 10 cell systems, including anti-inflammatory, antifibrotic, and anticancer activities. However, it is essential to note that C15 is not a recognized or approved medication for clinical use, and there is no standard dosing, duration, or treatment regimen available for C15.
- Without FDA or similar regulatory body approval, healthcare providers cannot legally prescribe C15 for medical treatment.
- If you're interested in experimental compounds for therapeutic purposes, you should consult with healthcare professionals about approved alternatives that have established safety and efficacy profiles.
- Research compounds typically require years of rigorous testing before determining appropriate therapeutic guidelines, including pharmacokinetics, safety profiles, and effective dosing strategies. Until such research is completed and regulatory approval is obtained, no legitimate therapeutic guidelines can be provided for C15, and healthcare providers should prioritize evidence-based treatments that have been proven to improve morbidity, mortality, and quality of life 1.